EUVIMEDEUVIMED entdecken
Open Access

Upadacitinib in Rheumatoid Arthritis After Prior TNF Inhibitor Failure: A 12-Month Multicenter Real-World Study

Umut Bakay, Nedim Kaban

Journal of Clinical Practice and Research · 17.08.2026 · 430-436

DOI: 10.14744/cpr.2026.21047 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Practice and Research, online erschienen am 17.08.2026. Verfasst von Umut Bakay und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatology, Denizli State Hospital, Denizli, Türkiye. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Patients with rheumatoid arthritis who do not achieve an adequate response to tumor necrosis factor inhibitors remain difficult to manage in routine clinical practice. Data from daily clinical care regarding selective JAK1 inhibition in this setting are limited. This study aimed to evaluate the 12-month effectiveness and safety of upadacitinib in Turkish patients with rheumatoid arthritis and previous tumor necrosis factor inhibitor failure. Materials and Methods: This retrospective multicenter study included adult patients with rheumatoid arthritis treated at two tertiary rheumatology centers who initiated upadacitinib at a dose of 15 mg/day after the failure of at least one tumor necrosis factor inhibitor. Disease activity, inflammatory markers, and functional status were assessed at baseline and at 3, 6, and 12 months using validated composite indices and patient-reported outcome measures. Changes over time were analyzed using repeated-measures statistical methods. Safety outcomes were collected from routine clinical follow-up records.

Results

Forty patients were included in the analysis, with a mean age of 48.4 years, and 62.5% were female. Consistent improvements were observed across disease activity measures throughout follow-up. At month 12, ACR20/50/70 response rates reached 87.5%, 77.5%, and 40.0%, respectively. Additionally, 45.0% of patients achieved low disease activity or remission according to the SDAI. Functional status improved in parallel with reductions in inflammatory and clinical parameters. No serious adverse events were observed during the 12-month follow-up, while the reported adverse events were mild.

Conclusion

Upadacitinib demonstrated sustained effectiveness and acceptable tolerability in patients with rheumatoid arthritis who had previously failed tumor necrosis factor inhibitor therapy in routine clinical practice.

Schlagwörter

Stichwörter der Autor:innen

Janus kinase inhibitorsTNF inhibitor failurereal-world evidencerheumatoid arthritisupadacitinib

Autor:innen und Institutionen

  • Department of Rheumatology, Denizli State Hospital, Denizli, Türkiye.
  • Department of Rheumatology, Çanakkale State Hospital, Çanakkale, Türkiye.

Zitieren

APA

Bakay, U., & Kaban, N. (2026). Upadacitinib in Rheumatoid Arthritis After Prior TNF Inhibitor Failure: A 12-Month Multicenter Real-World Study. Journal of Clinical Practice and Research, 430-436. https://doi.org/10.14744/cpr.2026.21047

Vancouver

Bakay U, Kaban N. Upadacitinib in Rheumatoid Arthritis After Prior TNF Inhibitor Failure: A 12-Month Multicenter Real-World Study. Journal of Clinical Practice and Research. 2026:430-436. doi:10.14744/cpr.2026.21047

BibTeX
@article{Bakay2026,
  author = {Bakay, Umut and Kaban, Nedim},
  title = {Upadacitinib in Rheumatoid Arthritis After Prior TNF Inhibitor Failure: A 12-Month Multicenter Real-World Study},
  journal = {Journal of Clinical Practice and Research},
  year = {2026},
  pages = {430--436},
  doi = {10.14744/cpr.2026.21047}
}
Kostenlos starten →